Answers are grounded in this paper and cite their sources.
Recombinant proteins exhibit significant promise as antiviral therapeutics. Here, we present a nanotherapeutic platform that, owing to its unique ability to self-assemble, can present multiple functionalities at the liquid–liquid interface. We genetically modified the sequence of an amphiphilic plant-derived protein called oleosin to induce spontaneous self-assembly into micellar nanoparticles. Using SARS-CoV-2 as a model, we demonstrate the potential of a recombinant protein nanoparticle to inhibit two different stages of viral infection. Oleosin variants were engineered to present miniproteins 1) that block the SARS-CoV-2 spike protein binding with human ACE2 receptors and 2) that inhibit virus-cell membrane fusion. Micellar nanoparticles assembled from these proteins are multivalent and bifunctional and achieved potent inhibition of the virus with an IC50 of less than 8 nM, which was more than an order of magnitude lower than that from monofunctional particles. This strategy demonstrates a promising path for developing a single protein nanoparticle capable of inhibition of multiple stages of a viral infection using solely recombinant techniques.
No takes yet. Share an insight, caveat, or question.
Pham et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: